Engystol
Engystol ®
Engystol® is produced in Germany and marketed by Biologische Heilmittel Heel GmbH for more than 60 years and marketed in Greece by A.S.K. Pharmaceutical, as an OTC medicine in tablet form.
The aim of treatment with Engystol® is to activate and support the body’s endogenous defense mechanisms and thus to strengthen the natural immune response in cases of upper respiratory viral infection, resulting in milder symptoms and shorter recovery times. Taken either preventively or at the first signs of a cold, Engystol® may prevent the development of acute symptoms(fever, bone aches, muscle aches).
Characteristics
Vincetoxicum hirundinaria
Stimulation of the endogenous defence mechanisms with sympathetic action.
Sulphur
Reactant in all chronic diseases e.g. acute and chronic inflammation of the respiratory, hepatic and gastrointestinal system, catarrh of the upper respiratory tract, dyspnea, bronchial asthma, throbbing headache.
Suitability
For the whole family (children above 6 years)
High risk persons or persons susceptible to seasonal viral infections.
Option for long term treatment.
Option for monotherapy or combination treatment.
Persons with otitis, sinusitis or dermatitis should consult their doctor before using Engystol.
Health professionals
- Engystol Leaflet
- Citations
- Product Approved by EOF-Marketing Authorization Number 61574/18 / 9-5-2019.
- Wronski S, Dannenmaier J, Schild S, Macke O, MuÈller L, Burmeister Y, et al. (2018).Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity. PLoS ONE 13(4): e0195822. https://doi. org/10.1371/journal.pone.0195822
- Wagner H et al. Influence of Homeopathic Drug Preparations on the Phagocytosis Capability of Granulocytes. Biol Ther 1986; XI(2):43-4.
- Wagner H. Examination of the immune stimulation effect of some plant homeopathic drugs. Biol Ther 1986;IV(2):21-27.
- Fimiani V, Cavallaro A, Ainis O, Bottari C. Immunomodulatory effect of the homoeopathic drug Engystol-N on some activities of isolated human leukocytes and in whole blood. Immunopharmacol Immunotoxicol 2000;22(1):103-115.
- Roeska K, Seilheimer B. Antiviral activity of Engystol® and Gripp-Heel®: an in-vitro assessment. J Imm Based Ther Vacc 2010;8:6.
- Enbergs H. Effects of the homeopathic preparation Engystol® on interferon- production by human T-lymphocytes. Immunol Invest 2006;35:19-27.
- Oberbaum H, Glatthaar-Saalmüller B, Stolt P, Weiser M. Antiviral Activity of Engystol®: an in vitro analysis. J Altern Complement Med 2005;11(5):855-862.
- Torbicka E, Brzozowska-Binda A, Wilczynski J, Uzerowicz A. RSV Infections in Infants: Therapy with a Homeopathic Preparation. Biomed Ther 1998;XVI(4):256-260.
- Siewierska K, Denys A., Efficacy of preoperative immunoprophylaxis in patients with neoplastic diseases (I). Int Rev Allergol Clin Immunol 1999;5(1);39-45.
- Matusiewicz R. The effect of a homeopathic preparation on the clinical condition of patients with corticosteroid-dependent bronchial asthma. Biomed Ther 1997;XV(3): 70-74.
- Heilmann A. A combination injection preparation as a prophylactic for flu and common colds. Biol Ther 1994;VII(4):249-253.
- Herzberger G, Weiser M. Homeopathic Treatment of Infections of Various Origins: A Prospective Study. Biomed Ther 1997;XV(4):123-127.
- Schmiedel V, Klein P. A complex homeopathic preparation for the symptomatic treatment of upper respiratory infections associated with the common cold: an observational study. Explore 2006;2:109-114.
Report side effects
- How can I report side effects?
Reporting of suspected adverse reactions.
Healthcare professionals are asked to report any suspected adverse reactions via the National Organization of Medicines. If you are a patient and you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the package leaflet. You can report adverse reactions with the following options :
1)Electronic submission through EOF’s website http://www.eof.gr/web/guest/yellowgeneral
2) Dispatching the Yellow card in hard copy via mail to EOF to the Department of Adverse Reactions (Mesogeion 284, Cholargos 15562)
3) Communication with the Department of Adverse Reactions via telephone : 213.20.40.380-337
4) Submission of the yellow card via fax at 210.6549.585
